La cadena de opciones muestra datos clave de las opciones de acciones de Akoya Biosciences a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para Akoya Biosciences..

Akoya Biosciences (NASDAQ:AKYA) Bolsa, Cadena de Opciones

AKOYA BIOSCIENCES INC

Akoya Biosciences

Akoya Biosciences Inc is a life sciences technology company. It is delivering spatial biology solutions focused on transforming discovery, clinical research and diagnostics. Its PhenoCycler (formerly CODEX) and PhenoImager (formerly Phenoptics) platforms, reagents, software, and services, It offer end-to-end solutions to perform tissue analysis and spatial phenotyping across the full continuum from discovery through translational and clinical research and diagnostics.

Akoya Biosciences Inc

WIIM

SPDR Dow Jones Industrial Average ETF Trust

Major indexes are higher after President Trump said the US signed a deal with China, with China's Ministry of Commerce reportedly confirming a trade framework. Israel-Iran ceasefire efforts and stronger-than-expected consumer sentiment data may also be lifting market outlook.

The U.S. Food and Drug Administration (FDA) approved label updates for Bristol Myers Squibb &amp; Co.&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>) CAR T cell therapies, Breyanzi (lisocabtagene maraleucel; liso-cel) for large B cell lymphoma (LBCL) and other lymphomas and Abecma (idecabtagene vicleucel; ide-cel) <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">for multiple myeloma</a>.
In the first quarter of 2025, Bristol Myers Squibb reported Abecam sales of $103 million, up 26% year over year, and Breyanzi sales <a target="_blank" href="https://www.benzinga.com/general/biotech/25/04/44986472/bristol-myers-delivers-upbeat-2025-forecast-after-beating-q1-wall-street-expectations-says-guidance-includes-china-tariffs-impact" rel="noreferrer noopener">jumped 146% to $204 million</a>.
The company said in a statement on Thursday that these label updates reduce certain patient monitoring requirements and remove the Risk Evaluation and Mitigation Strategy (REMS) programs that had been in place since each product <a target="_blank" href="https://www.benzinga.com/pressreleases/25/06/b46131412/u-s-food-and-drug-administration-approves-streamlined-patient-monitoring-requirements-and-removal-" rel="noreferrer noopener">was initially approved</a>.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/legal/25/06/46098969/bristol-myers-faces-scrutiny-for-allegedly-rigging-market-on-2b-cancer-drug" rel="noreferrer noopener">Bristol Myers Faces Scrutiny For Allegedly Rigging Market On $2 Billion Cancer Drug</a>
The company says about 2 in 10 eligible patients receive it due to the confluence of complex logistical and geographic barriers affecting patients and providers.
The FDA has approved the reduction or removal of specific patient monitoring requirements for Breyanzi and Abecma across both labels.
These prolonged requirements burdened healthcare delivery systems and certain patients and their care partners, particularly those who live far from certified cell therapy treatment centers.
Driving restrictions post-treatment have been reduced from eight weeks to two weeks. The requirement to remain within proximity of a healthcare facility after infusion has also been shortened from four weeks to two weeks.
The FDA has also approved the removal of the REMS requirement from each product label. A REMS program is often required to help mitigate known or potential risks associated with new drugs or therapies.
The FDA has since determined that the established management guidelines and extensive experience of the medical hematology/oncology community are sufficient to diagnose and manage the risks of side effects, including cytokine release syndrome (CRS) and neurologic toxicities (NTs), without a REMS for the class of CD19- and BCMA-directed autologous CAR T cell therapies.
In April 2024, the FDA said it would now&nbsp;require boxed warnings, the highest safety-related caution for medications, for all chimeric antigen <a target="_blank" href="https://www.benzinga.com/general/biotech/24/04/38334543/fda-mandates-boxed-warning-for-bristol-myers-johnson-johnson-car-t-based-blood-cancer-therapies" rel="noreferrer noopener">receptor (CAR) T-cell therapies</a>.&nbsp;
According to the agency, these blood cancer treatments may pose a&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/24/01/36736043/focus-on-bristol-myers-gilead-sciences-johnson-johnson-novartis-fda-to-issue-classwide-black-box-" rel="noreferrer noopener">risk of secondary cancers</a>.
Price Action: BMY stock is trading higher by 0.40% to $46.84 last check Friday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/health-care/25/06/46139132/spain-accuses-novo-nordisk-of-covert-advertising-for-prescription-weight-loss-drugs" target="_blank" rel="noreferrer noopener">Spain Accuses Novo Nordisk Of Covert Advertising For Prescription Weight-Loss Drugs</a></li>
</ul>
Photo via Shutterstock

Biotech

Large Cap

News

Health Care

General

FDA Eases Rules For Bristol Myers' Cell Therapies For Blood Cancers

Citigroup analyst Ygal Arounian maintains Bumble (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMBL#NASDAQ">BMBL</a>) with a Neutral and raises the price target from $4.8 to $7.

Price Target

Analyst Ratings

BMBL

Citigroup Maintains Neutral on Bumble, Raises Price Target to $7

SEED

Origin Agritech shares are trading lower after the company reported H1 financial results.

Westinghouse Air Brake (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WAB#NYSE">WAB</a>) has outperformed the market over the past 5 years by 14.53% on an annualized basis producing an average annual return of 29.34%. Currently, Westinghouse Air Brake has a market capitalization of $35.66 billion. 
Buying $100 In WAB: If an investor had bought $100 of WAB stock 5 years ago, it would be worth $363.36 today based on a price of $208.38 for WAB at the time of writing.
<h3>Westinghouse Air Brake's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1751038214_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

$100 Invested In Westinghouse Air Brake 5 Years Ago Would Be Worth This Much Today

Vor Biopharma shares are trading higher after Baird raised its price target on the stock from $0.25 to $1.

<figure class="wp-block-image size-full"><img loading="lazy" decoding="async" width="900" height="600" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/27074615/Yusys-0627-900x600-1.png" alt="" class="wp-image-14976" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/27074615/Yusys-0627-900x600-1.png 900w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/27074615/Yusys-0627-900x600-1-300x200.png 300w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/27074615/Yusys-0627-900x600-1-768x512.png 768w" sizes="(max-width: 900px) 100vw, 900px" /></figure>
The Baidu-backed provider of technology services for banks reported falling revenue last year, reflecting a challenging environment for its customers
<h4 class="wp-block-heading">Key Takeaways:</h4>
<ul class="wp-block-list">
<li>Shenzhen-listed Yusys has filed for a Hong Kong IPO at a time when its bank customers are struggling</li>
<li>The company's revenue dropped by a quarter last year, forcing it to aggressively cut costs to maintain its profits</li>
</ul>
Getting investors excited about anything related to banking in China looks like a tough sell right now, as lenders grapple with multiple issues flowing from the nation's sluggish economy.
And yet that's what&nbsp;Yusys Technologies Co. Ltd.&nbsp;(300674.SZ) is trying to do as it files for a Hong Kong IPO to complement its existing listing in Shenzhen. The big challenge for the Baidu-backed company will be finding ways to convince investors of the big potential for its business helping China's banks upgrade their technology, even if that potential may lie several years down the road.
Banking isn't a sexy business to begin with, and it isn't growing fast in China. The country's weak economy has softened demand for borrowing by both consumers and companies, dampening business for banks. Those same banks also need to be extra cautious about the loans they make to avoid getting hit by defaults from shaky borrowers. Such constraints are pressuring bank profits, leading them to spend less on third-party services like the ones Yusys supplies.
Yusys' financial performance is "directly exposed to risks inherent in the banking industry," the company said in its recently filed&nbsp;<a href="https://www1.hkexnews.hk/app/sehk/2025/107460/documents/sehk25061801848.pdf">IPO document</a>.
Yusys' latest annual results show how the growing chill for Chinese banks is infecting their third-party suppliers. The company's revenue dropped by a quarter to about 4 billion yuan ($557 million) last year, according to its prospectus filed last Thursday. It derives most of its revenue from services that help banks digitalize their operations, and its customers include China's "big four" national banks, as well as the country's monetary authority and policy lenders.
The big four banks' combined profit grew just 2% last year as they struggled to boost lending. Their weak loan growth was compounded by declines in interest margins as China's central bank cut interest rates to stimulate the economy. The outlook for banks continues to be bleak this year as well, as economic conditions in China remain gloomy despite various government efforts to stimulate spending.
Despite the falling revenue last year, Yusys managed to record net profit growth through a cost reduction campaign. It may resort to more cost-cutting this year to shore up its profits, even though such a strategy could undermine its longer-term prospects.
Leading last year's cost cuts were Yusys' 24% reduction in R&amp;D spending, the largest component of its operating expenses. More specifically, the company slashed expenses related to benefits for R&amp;D personnel, which account for more than 90% of spending for the category. Yusys attributed the steep cuts to its shifting resource allocation based on future plans and business requirements.
That hardly looks promising since Yusys is a technology company and thus needs to continuously enhance its offerings to retain existing customers and find new ones. Innovation is crucial for the company, particularly because it operates in a highly competitive sector. In its prospectus, the company says it is the largest listed provider of banking fintech services in China. But it also points out its market share is just 2%, showing there are lot of competitors looking to take away its business.
<h4 class="wp-block-heading">Firmly profitable</h4>
That said, Yusys may still appeal to investors looking for a company that has well-established operations and is firmly profitable. It has been around for quite some time, founded in 1999 and going public in New York eight years later, before privatizing in 2013. Five years later, it became a publicly traded company again by listing on Shenzhen's Nasdaq-style ChiNext board for growth companies. Its current investors include Baidu, which hold a 3.6% stake.
Yusys has served more than 1,000 customers in the last three years and has been profitable throughout that time. The company's business should indeed have strong demand, especially in the current market where China is encouraging companies to make technology upgrades as one of its many economic stimulus measures. Banks in China, and globally as well, are using technology like big data and AI to cut costs and improve the quality of their services and decision-making.
Technology spending by financial institutions across the world will increase about 11% annually over the next five years to reach $990 billion in 2029, according to a third-party projection included in Yusys' prospectus. That should bode well for Yusys and its peers, since a significant amount of that spending is expected to go to the purchase of technology services provided by outside companies.
Yusys has won some significant projects this year, including the development of a platform for data management, regulatory compliance and analytics for the London branch of a major bank.
Its services can be even more attractive for smaller financial institutions that lack internal resources to develop their own digital capabilities. In the first quarter of this year, a number of regional banks in China adopted the company's upgraded chatbot software.
Yet its customers are likely to rein in their own spending on third-party services as their business suffers in China's slowing economy. Yusys says it is looking to win more business from foreign banks to offset that risk, but its revenue from overseas customers is negligible for now.
Yusys' Shenzhen-listed shares have risen substantially since its Shenzhen IPO to trade at a healthy price-to-earnings (P/E) ratio of 47 and a decent price-to-sales (P/S) ratio of 5. By comparison, Tencent-backed&nbsp;Linklogis&nbsp;(9959.HK), which provides cloud-based software-as-a-service (SaaS) platforms for supply-chain financing, is losing money and trades at a lower P/S ratio is 3.3. The China-listed shares of the big four state-run banks also trade at P/S ratios in the 3 to 4 range.
Whether Yusys can fetch a higher valuation than its peers with the Hong Kong listing could be challenging, since Hong Kong investors often value companies lower than their Mainland Chinese counterparts. The company's revenue is expected to return to growth this year, with seven analysts polled by Yahoo Finance forecasting an 11% rise to 4.4 billion yuan. But even with that growth, the figure would still be well below its 2023 revenue,
Such lackluster prospects may not win over investors to Yusys' IPO, especially as it makes its listing into one of the hottest – but also most crowded – IPO markets that Hong Kong has seen for several years.

Asia

Equities

IPOs

Opinion

Yusys Seeks A Second Listing In Hong Kong

<a href="https://www.nytimes.com/2025/06/27/business/g7-tax-plan-trump.html?searchResultPosition=1">https://www.nytimes.com/2025/06/27/business/g7-tax-plan-trump.html?searchResultPosition=1</a>

'G7 Backs Plan for 'Side-by-Side' Tax System to Avoid U.S. Fight'- New York Times

Attention is shifting from cryptocurrencies to equities and publicly traded companies like Robinhood Markets (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOOD#NASDAQ">HOOD</a>), Coinbase Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COIN#NASDAQ">COIN</a>), and Circle Internet Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRCL#NYSE">CRCL</a>), which have surged ahead in <a href="https://www.benzinga.com/etfs/broad-u-s-equity-etfs/25/06/46131195/cathie-woods-thursday-crypto-moves-ark-unloads-nearly-25-million-in-coinbase-block-stocks">performance over the past month</a>.
What Happened: In an X <a href="https://x.com/MilkRoadDaily/status/1938318830981570978">post</a> on June 27, Milk Road Daily pointed out this outperformance.
Circle has led the pack with a 162% return in the last 30 days, while Coinbase and Robinhood gained between 30% and 35% during the same period. 
Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>), Ethereum (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>), and Solana (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/sol/usd">SOL</a>) logged negative returns ranging from -2% to -18% over the same timeframe.
Scarcity Meets Demand
There are relatively few crypto-linked public equities available, yet institutional and retail investors are hungry for exposure to crypto-adjacent plays, especially ones that have real revenue, growth potential and U.S. government support.
Token vs. Equity Market Dynamics
While equities benefit from limited supply and strong fundamentals, the token market is suffering the opposite fate as capital flows into tokens are muted compared to past cycles. 
At the same time, the number of tokens continues to explode, creating over-saturation and weakening price performance.
This mismatch of low demand and excessive supply is weighing heavily on altcoins, many of which are bleeding value despite brief speculative rallies.
Also Read: <a href="https://fr.benzinga.com/quote/cryptocurrency/25/06/46112072/coinbase-is-the-amazon-of-crypto-services-price-target-boosted-to-510-bernstein">Coinbase Is The &#8216;Amazon Of Crypto Services&#8217;, Price Target Boosted To $510: Bernstein</a>
Why It Matters: Crypto trader ResDegen <a href="https://x.com/resdegen/status/1937588394114142462">noted</a> that Robinhood, Circle, and Coinbase have clear business models, real revenue streams, and growing legitimacy with regulators. 
They offer a tangible value proposition that's drawing capital away from more speculative crypto assets.
As Kaizen <a href="https://x.com/KAIZ3NS/status/1936096315391312221">noted</a> on X, one of the defining features of this cycle is that only a handful of stocks and coins have shown real outperformance, namely crypto equities and a few large caps. 
TradFi currently has a stronger appetite for crypto-linked equities than for alt tokens.
Even Web3-native investors are beginning to shift their view. 
Trader David Arnal <a href="https://x.com/davidarngar/status/1936117933907787929">said</a> he considers Coinbase a safer long-term bet than even Bitcoin, citing teal revenue, government support and a market capitalization comparable to Solana. 
"COIN is the best stock to own for the next few months," he added.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/crypto/cryptocurrency/25/06/46097909/robinhood-ceo-highlights-retail-investor-interest-in-nvidia-tesla-despite-middle-east-tensions-barely-a-blip">Robinhood CEO Highlights Retail Investor Interest In Nvidia, Tesla Despite Middle East Tensions: &#8216;Barely A Blip&#8217;</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Fintech news covering the emerging Financial Technology services sector

Fintech

$BTC

$ETH

$SOL

COIN

CRCL

HOOD

Bitcoin, Ethereum, Solana Lag Behind Robinhood, Circle, Coinbase: Why Do Crypto Stocks Outperform Coins?

Shares of autonomous driving company Pony AI Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PONY#NASDAQ">PONY</a>) are surging this week, driven by reports of a potential <a href="https://www.benzinga.com/trading-ideas/movers/25/06/46129177/pony-ai-stock-pops-on-report-uber-is-in-talks-with-travis-kalanick-to-invest-in-potential-deal">takeover deal</a> involving Uber Technologies Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UBER#NYSE">UBER</a>) and its co-founder, Travis Kalanick. The preliminary talks would reportedly result in Kalanick running Pony AI, though financial details and Uber&#8217;s ultimate role remain unclear.
What Else: This news compounded an already positive week for the company. On Monday, Pony AI was added to the Nasdaq Golden Dragon China Index, a <a href="https://www.benzinga.com/trading-ideas/movers/25/06/46092236/pony-ai-rides-high-after-nasdaq-golden-dragon-china-index-inclusion">key benchmark</a> for U.S.-listed Chinese firms. The inclusion, which makes Pony AI the only pure-play autonomous vehicle company on the index, sent shares soaring nearly 17% on Monday.
The combination of the index inclusion and takeover speculation has investors buzzing. This follows last month&#8217;s partnership announcement with Uber to deploy robotaxis, highlighting the company&#8217;s rapid advancements.
The potential for Kalanick to re-engage with the Uber ecosystem he helped build could add a compelling dimension to the future of the autonomous driving landscape.
Price Action: PONY shares are trading higher by 25% to $14.55 this week. The stock has a 52-week high of $23.88 and a 52-week low of $4.11.
Read Also: <a href="https://www.benzinga.com/markets/tech/25/06/45817700/pony-ai-begins-testing-futuristic-robotaxis-in-china-mass-rollout-could-be-next">Pony.ai Begins Testing Futuristic Robotaxis In China, Mass Rollout Could Be Next</a>
<h2 class="wp-block-heading">How To Buy PONY Stock</h2>
Besides going to a brokerage platform to purchase a share &#8211; or fractional share &#8211; of stock, you can also gain access to shares either by buying an exchange traded fund (ETF) that holds the stock itself, or by allocating yourself to a strategy in your 401(k) that would seek to acquire shares in a mutual fund or other instrument. 
For example, in Pony AI&#8217;s case, it is in the Information Technology sector. An ETF will likely hold shares in many liquid and large companies that help track that sector, allowing an investor to gain exposure to the trends within that segment.
Image: Shutterstock

PONY

UBER

Pony AI Stock Surges 25% This Week: What's Going On?

LSAK

LSAK stock has given up its prior gain. Lesaka Technologies shares were trading higher after the company announced it has agreed to acquire Bank Zero Mutual.

IMAB

I-MAB shares are trading higher after Needham raised its price target on the stock from $4 to $5 and maintained a Buy rating.

HC Wainwright &amp; Co. analyst Yi Chen reiterates Lipocine (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LPCN#NASDAQ">LPCN</a>) with a Buy and maintains $8 price target.

Reiteration

LPCN

HC Wainwright & Co. Reiterates Buy on Lipocine, Maintains $8 Price Target

Rocket Lab Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RKLB#NASDAQ">RKLB</a>) stock is moving higher Friday on possible continued momentum after the company launched its 67th Electron rocket on a dedicated mission for radio frequency geospatial <a href="https://www.benzinga.com//node/46119769">analytics provider HawkEye 360</a>.
The Details: The company said the mission, named "Get The Hawk Outta Here," successfully deployed four satellites to a 520 km circular low Earth orbit. The launch took place June 27 NZT from Launch Complex 1 in Mahia, New Zealand, and marked the second of three dedicated launches for HawkEye 360 under a multi-launch contract.
"Today's launch for HawkEye 360 was another seamless ride to orbit for Electron, with four satellites deployed with absolute precision to support the growth of HawkEye 360's constellation in low Earth orbit," said Rocket Lab founder and CEO Sir Peter Beck.
Rocket Lab is now scheduling its next launch, "Symphony In The Stars," to take place less than 48 hours later on June 28 NZT. If successful, it will mark the fastest turnaround between missions in the company's history. The upcoming launch, Rocket Lab's 68th overall and tenth of the year, will deliver a single spacecraft to a 650 km circular Earth orbit for a confidential commercial customer.
See Also: <a href="https://www.benzinga.com/m-a/25/06/46142142/biocryst-just-ditched-its-europe-business-heres-why-investors-are-cheering">BioCryst Just Ditched Its Europe Business — Here&#8217;s Why Investors Are Cheering </a> RKLB Price Action: At the time of writing, Rocket Lab stock is trading 1.22% higher at $36.58, according to data from <a href="https://www.google.com/url?sa=t&amp;source=web&amp;rct=j&amp;opi=89978449&amp;url=https://www.benzinga.com/pro/&amp;ved=2ahUKEwjB7c6765GOAxXxGVkFHYDlNh0QFnoECB4QAQ&amp;usg=AOvVaw0xIsPvjIcIIsWev01-6zR2">Benzinga Pro</a>.
Image via Shutterstock

Movers

RKLB

Rocket Lab Stock Is Moving Higher Friday: What's Going On?

ZIM Integrated Shipping shares are trading higher after Barclays raised its price target on the stock from $14.2 to $14.8.

HC Wainwright &amp; Co. analyst Yi Chen assumes Edesa Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EDSA#NASDAQ">EDSA</a>) with a Buy rating and announces Price Target of $5.

Initiation

EDSA

HC Wainwright & Co. Assumes Edesa Biotech at Buy, Announces Price Target of $5

Citigroup analyst Paul Lejuez maintains Nike (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NKE#NYSE">NKE</a>) with a Neutral and raises the price target from $57 to $68.

Citigroup Maintains Neutral on Nike, Raises Price Target to $68

VNET

VNET Group shares are trading higher after the company raised its FY25 revenue and adjusted EBITDA guidance. Additionally, the company announced it authorized a $50 million share repurchase program.

ODDITY Tech shares are trading higher after B of A Securities raised its price target on the stock from $68 to $80.

WF Holding Shares Halted On Circuit Breaker To The Downside, Stock Now Up 86.3%

Press Releases

Akoya Biosciences and Enable Medicine Launch the Largest Commercially Available Single-Cell Spatial Proteomics Atlas

Legal

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates PPBI, SSBK, AKYA on Behalf of Shareholders

Quanterix and Akoya Biosciences Announce Amended Merger Agreement

Kent Lake Issues Statement on Quanterix's Blatant Disregard for Will of Shareholders

AKOYA BIOSCIENCES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Akoya Biosciences, Inc. - AKYA

Earnings

Akoya Biosciences Reports First Quarter 2025 Financial Results

Peraso Inc.'s (NASDAQ: PRSO) Beamforming Technology Gains Military Traction – See More Stocks Inside

Small Cap

New Data and Deal Flow Signal a Turning Point for Precision-Driven Cancer Biotechs

Kent Lake Responds to Quanterix's Post-Effective Amendment and Akoya's Superior $1.40-per-Share Alternative Proposal

AKOYA BIOSCIENCES INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Akoya Biosciences, Inc. - AKYA

Comments

Akoya Biosciences

Akoya Biosciences (AKYA) Opciones

Akoya Biosciences (NASDAQ:AKYA) Bolsa, Cadena de Opciones

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL